

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/40024 A1

- (51) International Patent Classification⁷: **A61K 31/495**, (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/EP01/11952
- (22) International Filing Date: 16 October 2001 (16.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 00124815.2 14 November 2000 (14.11.2000) EP
- (71) Applicant (*for all designated States except US*): **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **BARTOSZYK, Gerd** [DE/DE]; Kreuzstrasse 57, 64331 Weiterstadt (DE).
- (74) Common Representative: **MERCK PATENT GMBH**; Frankfurter Strasse 250, 64293 Darmstadt (DE).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/40024 A1

(54) Title: NOVEL USES OF COMBINED 5-HT_{1A} AGONISTS AND SEROTONIN REUPTAKE INHIBITORS

(57) Abstract: Use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT_{1A} receptor agonist, in particular 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbomoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-[4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl]-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in veterinary medicine for the treatment or prophylaxis of self directed traumatic disorders associated with behavioral stressors and compulsive disorders associated with behavioral stressors.

Novel uses of combined 5-HT_{1A} agonists and serotonin reuptake inhibitors

- 5 The present invention relates to the use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT_{1A} receptor agonists for the manufacture of a medicament for use in veterinary medicine for the treatment or prophylaxis of disorders associated with behavioral stressors.
- 10 Particularly, the present invention relates to the use of combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT_{1A} receptor agonists chosen from the group consisting of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-
- 15 carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in veterinary medicine for the treatment of self directed traumatic disorders associated with behavioral stressors and/or compulsive disorders associated with behavioral stressors.
- 20 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, physiologically acceptable salts thereof (US 5,532,241, column 7, lines 30 to 58) and a process (US 5,532,241, Example 4) by which it/they can be prepared are known from U.S. Patent US 5,532,241. The compound which
- 25 is referred to herein is described in the patent as a combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT_{1A} receptor agonist. Therefore, the use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable acid addition salts for the manufacture of a medicament for the treatment of depressive disorders, including the sub-type disorders major depressive disorder and
- 30 dysthymic disorder, for the treatment of anxiety disorders, for the treatment of psychiatric disorders like psychoses, schizophrenia or schizoaffective

disorder, for the treatment of cerebral infarct like stroke and cerebral ischemia, for the treatment of CNS disorders such as tension, for the therapy of side-effects in the treatment of hypertension (e.g. with α -methyldopa) and for the prophylaxis and therapy of cerebral disorders (e.g. migraine) is disclosed. Additionally, the use in endocrinology and gynecology is described, e.g. for the treatment of acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome or undesired puerperal lactation.

3-{4-[4-(4-Cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile, physiologically acceptable salts thereof (EP 0 736 525, page 3, lines 5, 26 and, page 8 lines 28 to page 9 lines 12) and a process (EP 0 736 525, Example 1) by which it/they can be prepared are known from EP 0 736 525. They show, in particular, actions on the central nervous system, especially 5-HT_{1A}-agonistic and 5-HT-reuptake inhibiting actions. Therefore they are suitable for the treatment of disorders of the central nervous system such as states of tension, depressions and/or psychoses and of side effects in the treatment of hypertension. Additionally, the use in endocrinology and gynecology is described, e.g. for the treatment of acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome or undesired puerperal lactation, and furthermore for the prophylaxis and therapy of cerebral disorders (e.g. migraine), in particular in geriatrics, similarly to certain ergot alkaloids and for the control of the sequelae of cerebral infarcts (apoplexia cerebri), such as stroke and cerebral ischaemias.

The invention had the object of providing novel uses for compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT_{1A} receptor agonists, in particular of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-

carbonitrile or a physiologically acceptable salt thereof, especially in the field of veterinary medicine.

5 It has been found that combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT_{1A} receptor agonists, in particular 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, also have activity against disorders associated with
10 behavioral stressors in veterinary medicine.

Disorders associated with behavioral stressors include self directed traumatic disorders associated with behavioral stressors (also known as self-injurious behavior) and compulsive disorders associated with
15 behavioral stressors (e.g. C.C. Pinney, The illustrated veterinary guide for dogs, cats, birds and exotic pets. McGraw Hill, 1992; U.A. Luescher, in: N.H. Dodman and L. Shuster (eds.): Psychopharmacology of Animal Behavior, Blackwell Science Inc., Malden, 1998, pp. 203-221).

Self directed traumatic disorders associated with behavioral stressors and
20 compulsive disorders associated with behavioral stressors result particularly in stereotyped behaviors in animals, a common problem for pet owners, breeders, zoo keepers and veterinarians. Self directed traumatic disorders are characterized by self-injurious behaviors such as acral lick dermatitis (ALD), flank sucking, spinning and tail chaising, nail biting and
25 checking of the rear end in dogs, psychogenic alopecia (hair pulling), tail attacking, pawing the face and hyperesthesia in cats or feather picking (trichotillomania) in birds.

Compulsive disorders are seen in other species, too, e.g. repetitive or ritualized pacing seen in zoo animals, cribbing, self-mutilation or weaving in
30 horses.

For example, intense animal keeping is characterized by high animal populations on restricted grounds. Animals kept under such conditions experience extreme stress and develop both traumatic and compulsive disorders, e.g. bar biting in pigs in meat-producing farms or feather picking in hens in egg-producing farms (e.g. M. Kiley-Worthinton, Behavioral problems of farm animals, Oriol Press, Stockfields, 1977; R.J. Young et al., Appl. Anim. Behav. Sci., 1994, 39: 237-247).

Amongst these disorders, in veterinary practice especially the self directed traumatic disorders, i.e. acral lick dermatitis in dogs, psychogenic alopecia in cats, feather picking in caged birds, and self-mutilation, cribbing and weaving in horses, are very common and usually the reason why pet owners consult a veterinarian (e.g. R.R. Keiper, Anim. Behav., 1970, 18: 353-357; C. Davis, Vet. Clin. N Am. Sm. An. Pract., 1991, 21: 1281-1288; C.C. Pinney, The illustrated veterinary guide for dogs, cats, birds and exotic pets. McGraw Hill, 1992; D.J. Stein and N.H. Dodman, Comp. Psychiatr., 1994, 35: 275-285).

Acral lick dermatitis is a condition characterized by excessive paw licking and scratching in dogs. This results in the characteristic dermatitis; other sequelae include acute and chronic osteomyelitis. Acral lick dermatitis, also known as lick granuloma, creates areas of hair loss and the production of lesions, which may range in size from several centimeters to the entire surface of the limb, finally inflamed and ulcerated causing discomfort, pain, and in severe cases crippling. Osteomyelitis represents a suppurative infection of bone tissue with a progressive course with signs of bone destruction and formation of atrophic foci in the bone; in some cases sequestra and false joints are formed. The disorder is seen in certain breeds of large dog (particularly prone are Doberman Pinscher, German Shephard, Great Danes, Golden Retriever, Labrador Retriever, Irish Setter, and Weimaraner), and may be more common in particular families within breeds (e.g. L. Veith, Canine Pract., 1986, 14: 15-22; J.J. Van Nes, J. Am.

Vet. Med. Assoc., 1986, 198: 157-160; S.D. White, J. Am. Vet. Med. Assoc., 1990, 202: 1073-1076; B.A. Goldberger and J.L. Rapoport, J. Anim. Hosp. Assoc., 1990, 27: 179-182; U.A. Luescher et al., Vet. Clin. N Am. Sm. Anim. Pract., 1991, 21: 401-413; K. Overall, J. Am. Vet. Assoc., 1994, 205: 1733-1741; U.A. Luescher, Vet. Intern., 1998, 10: 7-12).

Psychogenic alopecia is found in cats, where excessive depilation leads to bare patches (e.g. U.A. Luescher et al., Vet. Clin. N Am. Sm. Anim. Pract., 1991, 21: 401-413; J.W.S. Bradshaw et al., J. Appl. An. Behav. Sci., 1997, 52: 373-379; J. Dehasse, Appl. An. Behav., 1997, 52: 365-371; L.S. Sawyer et al., J. Am. Vet. Med. Assoc., 1999, 214: 71-74). Animal behaviorists have typically viewed the disorder as stress related. All strains are prone of psychogenic alopecia.

Feather picking in birds is seen in a range of avian species. Complications associated with this disorder include severe haemorrhage, infection, and hypothermia. It is also known that stress and confinement play a role in this behavior. Very prone are African greys and Timneh greys, budgerigars, rosellas, neophemas and other Australian parakeets, cockatoos, conures, electus parrots, lorikeets, lovebirds, and macaws (e.g. R.R. Keiper, Anim. Behav., 1970, 18: 353-357; D. Alderton, An essential reference for keeping more than 200 parrot family species, Salamander Books, 1992; G.A. Gallerstein, The complete bird owner's handbook, Macmillan, 1994; C. Davis, Vet. Clin. N Am. Sm. An. Pract., 1991, 21: 1281-1288; F. Iglauer and R. Rasim, J. Sm. An. Pract., 1993, 34: 564-566; P.S. Brodnick et al., J. Behav. Ther. Exp. Psychiatr., 1994, 25: 189-196; S. Blanchard, Pet Bird Report, 1995, 23; S.V. Juarbe-Diaz, J. Am. Vet. Med. Assoc., 2000, 1562-1564).

Self-mutilation behavior in horses consists of self-biting (flanks, limbs, lateral thoracic wall, pectoral area, tail) and other uncontrollable violent behaviors typically including spinning in circles, bucking, rubbing, kicking

out with hind limbs sometimes while nipping at the flank, shoulders or chest, and vocalization. In extreme cases, the horse can violently lunge its body or head into a wall or other solid subject. A single episode can last to several minutes uninterrupted, and episodes can be repeated for hours over a day. In addition to bite wounds, the most common injuries are to the legs and feet from spinning and kicking. Self-mutilation is most common in Arabian, Quarterhorse and American Standardbred stallions, although it occurs in both sexes and in a variety of other breeds (e.g. A.F. Frazer, The behavior of the horse, CAB International, Oxon, 1992; L.C. Winskill et al., Appl. An Behav Sci, 1996, 48: 25-25).

Cribbing behavior is the most well known stable vice. Horses bite an object, flexes its neck, pulls back with its teeth, and swallows air. Cribbing not only damages the house surroundings, but could threaten its life. Cribbing leads to weight loss, poor performance, gaseous colic, and excessive tooth wear (e.g. N.H. Dodman et al., Am. J. Vet. Res., 1987, 48: 311-319; M. Minero et al., Proc. Measuring Behav, 1996).

Weaving behavior in horses is an odd behavior in which the horse rocks from foreleg to foreleg for long amounts of time. Weaving generally occurs in horses which are kept in stalls (e.g. A.F. Frazer, The behavior of the horse, CAB International, Oxon, 1992).

Treatment of these disorders is extremely difficult and often resistant to any treatment.

Clomipramine hydrochloride, a tricyclic antidepressant drug with serotonin (5-HT) reuptake inhibiting properties, is used in dogs (e.g. P.A. Mertens and N.H. Dodman, Kleintierpraxis, 1996, 41: 313-392; R.A. Eckstein and B.L. Hart, J. Am. An. Hosp. Assoc., 1996, 32: 225-230; R.A. Casey, Vet. Rec., 1998, 142: 587-588; A.L. Podberscek et al., Vet. Rec., 1999, 145: 365-369), cats (e.g. L.S. Saxyer et al., J. Am. Vet. Med. Assoc., 1999, 214: 71-74; K. Seksel and M.J. Lindeman, Aust. Vet. J., 1998, 76: 317-321), and

birds (e.g. M.H. Grindlinger and E. Ramay, *Proc. Assoc. Avian Vet.*, 1992) .
Alternatively, selective serotonin (5-HT) reuptake inhibitors (SSRIs) such as
fluoxetine are used in such species including horses (e.g. K.L. Overall,
Can. Pract., 1996, 21: 20-24; P.A. Mertens, *ESVCE Newsletter*, 1997, 3: n°
5 4/5; H.G. Nurnberg et al., *Biol. Psychiatr.*, 1997, 41: 226-229; D. Wynchank
and M. Berk, *Depress. Anxiety*, 1998, 8: 21-23; J. Romatowski, *Feline
Pract.*, 1998, 26: 14-15). Finally, also dopamine antagonists such as
haloperidol have been reported to be effective in dogs, cats, birds and
horses (e.g. F. Iglauer and R. Rasim, *J. Sm. An. Pract.*, 1993, 34: 564-566;
10 H.G. Nurnberg et al., *Biol. Psychiatr.*, 1997, 41: 226-229; U.A. Luescher, in:
N.H. Dodman and L. Shuster (eds.): *Psychopharmacology of Animal
Behavior*, Blackwell Science Inc., Malden, 1998, pp. 203-221).

Although serotonin 5-HT_{1A} receptor agonists are not established as a
15 pharmacological treatment in animals, the 5-HT_{1A} receptor agonist
busprione has been proposed for dogs and cats (B.L. Hart et al., *J. Am.
Vet. Med. Assoc.*, 1993, 203: 254-258; K.L. Overall, *J. Am. Vet. Med.
Assoc.*, 1994, 205: 694-696; W. Jochle, *Tierärztl. Prax.*, 1998, 26: 410-
421). But is long known that 5-HT_{1A} receptor agonists reduce stress and
20 relieve anxiety in animals (e.g. J.E. Barrett and K.E. Vanover,
Psychopharmacology, 1993, 112: 1-12; G. Griebel, *Pharmac. Ther.*, 1995,
65: 319-395; F.G. Graeff et al., *Pharmacol. Biochem. Behav.*, 1996, 54:
129-141) and man (e.g. J.P. Feighner et al., *J. Clin. Psychiatr.*, 1982, 43:
103-108; A.F. Jacobson et al., *Pharmacotherapy*, 1985, 5: 290-296; J.J.
25 Sramek et al., *Depress. Anxiety*, 1999, 9: 131-134). Moreover, 5-HT_{1A}
receptor agonists have been shown be effective alone (J.P. Apter and L.A.
Allen, *J. Clin. Psychopharmacol.*, 1999, 19: 86-93) and particularly to
augment the effect of SSRIs (P.J. Markovitz et al., *Am. J. Psychiatr.*, 1990,
147: 798-800) in obsessive-compulsive disorders in humans which
30 resemble in various aspects (e.g. trichotillomania, onychophagia, obsessive
checking) self directed traumatic disorders and compulsive disorders in
animals (e.g. E. Yadin et al., *Pharmacol. Biochem. Behav.*, 1991, 40: 311-

315; J.L. Rapoport et al., Arch. Gen. Psychiatr., 1992, 49: 517-521; P.S. Bordnick et al., J. Behav. Ther. Exp. Psychiatr., 1994, 25: 189-196; D.J. Stein and N.H. Dodman, Comp. Psychiatr., 1994, 35: 275-285; H.G. Nurnberg et al., Biol. Psychiatr., 1997, 41: 226-229; H. Szechtman et al., Behav. Neurosci., 1998, 112: 1475-1485, Pol. J. Pharmacol., 1999, 51: 55-61). Therefore, the combination of selective serotonin (5-HT) reuptake inhibiting properties and 5-HT_{1A} receptor agonistic properties represent an advantage over either SSRIs or 5-HT_{1A} receptor agonists alone for the treatment of self directed traumatic disorders and compulsive disorders.

10

Accordingly, the present invention relates to the use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT_{1A} receptor agonists, in particular of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in veterinary medicine for the treatment of self directed traumatic disorders including acral lick dermatitis in dogs, psychogenic alopecia in cats and feather picking in birds, and/or compulsive disorders.

20

Accordingly, the present invention relates to the use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in veterinary medicine for the treatment of disorders associated with behavioral stressors.

25

The present invention relates furthermore to the use of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in veterinary medicine for the treatment of disorders associated with behavioral stressors.

30

A preferred salt of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

- 5 Therefore the invention relates to the use for the manufacture of a medicament for use in veterinary medicine for the treatment of disorders associated with behavioral stressors in which the pharmacologically acceptable salt of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
- 10

A preferred salt of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile is 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile hydrochloride.

- 15 Therefore the invention relates to the use for the manufacture of a medicament for use in veterinary medicine for the treatment of disorders associated with behavioral stressors in which the pharmacologically acceptable salt of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile is 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile hydrochloride.
- 20

- Additionally, the invention relates to the use of a pharmaceutical composition containing at least a compound being a combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT_{1A} receptor agonist, in particular 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, together with at least one solid, liquid or semiliquid excipient or adjunct for the treatment of disorders associated with behavioral stressors.
- 25
- 30

Thus the invention provides a pharmaceutical preparation for the treatment of disorders associated with behavioral stressors for use in veterinary medicine characterized in that it contains at least 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and/or one of its pharmaceutically acceptable salts and at least one auxiliary substance.

Thus the invention provides a pharmaceutical preparation for the treatment of disorders associated with behavioral stressors for use in veterinary medicine characterized in that it contains at least 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile and/or one of its pharmaceutically acceptable salts and at least one auxiliary substance.

Suitable excipients are organic or inorganic substances which are suitable for enteral (e.g. oral), parenteral or topical administration and which do not react with the active compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatine, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly. Forms which are used for oral administration are, in particular, tablets, pills, sugar-coated tablets, capsules, powders, granules, syrups, liquids or drops, forms for rectal administration are, in particular suppositories, forms for parenteral administration are, in particular, solvents, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants, and forms for topical administration are transdermal plasters, ointments, creams or powders. The active compounds may also be lyophilized and the resulting lyophilisates used for example for the preparation of injectable products. The abovementioned preparations can be in sterilized form and/or comprise auxiliaries such as glidants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, colourings, flavourings and/or other active ingredients, e.g. one or more vitamins.

The compounds, 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its pharmaceutically acceptable salts or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile and its pharmaceutically acceptable salts, according to the invention are preferably administered in analogy to other known commercially available preparations for the treatment of disorders associated with behavioral disorders in veterinary medicine. A unit dose will generally contain from 0.1 to 300 mg, preferably between approximately 0.1 (for small birds) and 100 mg (for large dogs), in particular 0.1, 0.5, 1, 5, 10, 30, 50, 100, 200, and 300 mg. The composition may be administered once or more times a day for example 2, 3 or 4 times daily. The daily dose is preferably between approximately 1 and 10 mg/kg of body weight. However, the specific dose for each recipient animal depends not only on the species but on all sorts of factors, for example on the activity of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, on the excretion rate, pharmaceutical substance combination and severity of the particular disorder to which the therapy relates. Oral administration is preferred; the appropriate dosage can typically be mixed with the food without major difficulty, but also peroral routes of administration (e.g. intramuscular or transdermal) can be utilized.

To prove the efficacy of the compounds according to the invention, the following clinical studies are described:

Example 1:

The aim of the study is to assess the efficacy of the compound treatment of acral lick dermatitis (ALD) in dogs in a multicenter, placebo-controlled study involving veterinarian practitioners (adopted from J.L. Rapoport et al., Arch. Gen. Psychiatr., 1992, 49: 517-521; D. Wynchank and M. Berk, Depress. Anxiety, 1998, 8: 21-23; A.L. Podberscek et al., Vet. Rec., 1999, 145: 365-369).

Forty dogs with ALD are treated with the compound 2 mg/kg twice daily or ,
or placebo, for 8 weeks. If necessary, the dose is adjusted according to the
clinical response. Owners rate both appearance of the lesion and licking
behavior weekly, and veterinarians rate pre- and post-treatment lesions.

5

Example 2:

The aim of the study is to assess the efficacy of the compound treatment of
psychogenic alopecia in cats in a multicenter, placebo-controlled study
involving veterinarian practitioners (according to K. Seksel and M.J.
Lindeman, Aust. Vet. J., 1998, 76: 317-321).

10

Twenty-eight cats with psychogenic alopecia are treated with the
compound with a starting dose of 1 mg/kg twice daily, or placebo, for 8
weeks. If necessary, the dose is adjusted according to the clinical response
Owners rate both appearance and size of the lesion weekly, and
veterinarians rate pre- and post-treatment.

15

Example 3:

The aim of the study is to assess the efficacy of the compound treatment of
feather picking in birds in a multicenter, placebo-controlled study involving
veterinarian practitioners (according to P.A. Mertens, ESVCE Newsletter,
1997, n° 4/5).

20

Twentyfour birds with feather picking are treated with the compound
3 mg/kg threetimes daily, or placebo, for a minimum of 4 weeks and up to 8
weeks. If necessary, the dose is adjusted according to the clinical
response. Owners rate both appearance and size of the feather-less lesion,
and veterinarians rate pre- and post-treatment (4 weeks and 8 weeks, in
case).

25

30

Patent Claims

1. Use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT_{1A} receptor agonists for the manufacture of a medicament for use in veterinary medicine for the treatment of disorders associated with behavioral stressors.
2. Use according to claim 1 wherein the compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT_{1A} receptor agonists are selected from the group consisting of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof.
3. Use according to claim 2 in which the physiologically acceptable salt of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
4. Use according to claim 2 in which the physiologically acceptable salt of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile is 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile hydrochloride.
5. Pharmaceutical preparation for the treatment of disorders associated with behavioral stressors for use in veterinary medicine characterized in that it contains at least one compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT_{1A} receptor agonist.
6. Pharmaceutical preparation according to claim 5 wherein the combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT_{1A} receptor

agonist is selected from the group consisting of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof.

5

10

15

20

25

30

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/11952

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/495 A61P25/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, MEDLINE,
PHARMAPROJECTS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 648 767 A (MERCK PATENT GMBH) 19 April 1995 (1995-04-19) cited in the application *cf. page 2, lines 23-30, page 7, lines 42-50, page 9, example 4	1-6
Y	DE 43 33 254 A (MERCK PATENT GMBH) 6 April 1995 (1995-04-06) *cf. abstract, page 8, example 4*	1-6
Y	DE 197 30 989 A (MERCK PATENT GMBH) 21 January 1999 (1999-01-21) *cf. abstract, page 2, lines 45-53* -/-	1-6

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

21 February 2002

Date of mailing of the international search report

04/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

StoItner, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/11952

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 736 525 A (MERCK PATENT GMBH) 9 October 1996 (1996-10-09) cited in the application *cf. page 2, lines 30-53, page 5, lines 45-47, page 6, example 1*	1-6
Y	WO 98 11068 A (BOETTCHER HENNING ;MERCK PATENT GMBH (DE); ARLT MICHAEL (DE); BART) 19 March 1998 (1998-03-19) *cf. page 2, lines 5-16, lines 31-35*	1-6
Y	US 5 532 241 A (BOETTCHER HENNING ET AL) 2 July 1996 (1996-07-02) *cf. abstract, col. 1, lines 35-41, lines 52-60, col. 8, lines 24-38, col. 12, example 7*	1-6
Y	WO 00 05225 A (AMSTERDAM CHRISTOPH VAN ;BOETTCHER HENNING (DE); MERCK PATENT GMBH) 3 February 2000 (2000-02-03) *cf. page 3, 3rd para. and page 4, lines 1-28, claim 7*	1-6

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11952

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0648767	A	19-04-1995	DE	4333254 A1	06-04-1995
			AT	153663 T	15-06-1997
			AU	679774 B2	10-07-1997
			AU	7424494 A	13-04-1995
			BR	1100891 A3	06-06-2000
			CA	2133152 A1	31-03-1995
			CN	1106811 A , B	16-08-1995
			CZ	9402370 A3	12-04-1995
			DE	59402902 D1	03-07-1997
			DK	648767 T3	22-12-1997
			EP	0648767 A1	19-04-1995
			ES	2105454 T3	16-10-1997
			GR	3024551 T3	31-12-1997
			HU	71833 A2	28-02-1996
			JP	7149762 A	13-06-1995
			NO	943616 A	31-03-1995
			PL	305216 A1	03-04-1995
			RU	2132848 C1	10-07-1999
			SK	118494 A3	10-05-1995
			US	5532241 A	02-07-1996
			ZA	9407622 A	16-05-1995
DE 4333254	A	06-04-1995	DE	4333254 A1	06-04-1995
			AT	153663 T	15-06-1997
			AU	679774 B2	10-07-1997
			AU	7424494 A	13-04-1995
			BR	1100891 A3	06-06-2000
			CA	2133152 A1	31-03-1995
			CN	1106811 A , B	16-08-1995
			CZ	9402370 A3	12-04-1995
			DE	59402902 D1	03-07-1997
			DK	648767 T3	22-12-1997
			EP	0648767 A1	19-04-1995
			ES	2105454 T3	16-10-1997
			GR	3024551 T3	31-12-1997
			HU	71833 A2	28-02-1996
			JP	7149762 A	13-06-1995
			NO	943616 A	31-03-1995
			PL	305216 A1	03-04-1995
			RU	2132848 C1	10-07-1999
			SK	118494 A3	10-05-1995
			US	5532241 A	02-07-1996
			ZA	9407622 A	16-05-1995
DE 19730989	A	21-01-1999	DE	19730989 A1	21-01-1999
			AU	731332 B2	29-03-2001
			AU	8730298 A	10-02-1999
			BR	9810607 A	11-07-2000
			CN	1264379 T	23-08-2000
			WO	9903855 A1	28-01-1999
			EP	0998474 A1	10-05-2000
			HU	0002718 A2	28-10-2001
			JP	2001510193 T	31-07-2001
			NO	20000216 A	17-01-2000
			PL	338075 A1	25-09-2000
			SK	352000 A3	12-06-2000
			TW	425398 B	11-03-2001
			US	6251908 B1	26-06-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11952

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 19730989	A	ZA 9806390 A	24-05-1999
EP 0736525	A	09-10-1996	
		DE 19512639 A1	10-10-1996
		AT 194595 T	15-07-2000
		AU 709708 B2	02-09-1999
		AU 5040896 A	17-10-1996
		BR 9601275 A	13-01-1998
		CA 2173418 A1	06-10-1996
		CN 1137036 A ,B	04-12-1996
		CZ 9600964 A3	16-10-1996
		DE 59605568 D1	17-08-2000
		DK 736525 T3	30-10-2000
		EP 0736525 A1	09-10-1996
		ES 2150039 T3	16-11-2000
		GR 3034514 T3	29-12-2000
		HU 9600876 A2	28-09-1998
		JP 9151174 A	10-06-1997
		NO 961346 A	07-10-1996
		PL 313632 A1	14-10-1996
		PT 736525 T	29-12-2000
		SI 736525 T1	28-02-2001
		SK 40396 A3	06-11-1996
		TR 970156 A2	21-03-1997
		US 6310068 B1	30-10-2001
		ZA 9602768 A	13-11-1996
WO 9811068	A	19-03-1998	
		DE 19637237 A1	19-03-1998
		AU 724374 B2	21-09-2000
		AU 4620397 A	02-04-1998
		BR 9712037 A	24-08-1999
		CN 1230180 A	29-09-1999
		CZ 9900824 A3	16-06-1999
		WO 9811068 A1	19-03-1998
		EP 0931067 A1	28-07-1999
		HU 9904521 A2	28-05-2000
		JP 2001500142 T	09-01-2001
		NO 991236 A	12-03-1999
		PL 332081 A1	30-08-1999
		SK 30399 A3	16-05-2000
		US 6258813 B1	10-07-2001
		ZA 9708194 A	03-03-1999
US 5532241	A	02-07-1996	
		DE 4333254 A1	06-04-1995
		AT 153663 T	15-06-1997
		AU 679774 B2	10-07-1997
		AU 7424494 A	13-04-1995
		BR 1100891 A3	06-06-2000
		CA 2133152 A1	31-03-1995
		CN 1106811 A ,B	16-08-1995
		CZ 9402370 A3	12-04-1995
		DE 59402902 D1	03-07-1997
		DK 648767 T3	22-12-1997
		EP 0648767 A1	19-04-1995
		ES 2105454 T3	16-10-1997
		GR 3024551 T3	31-12-1997
		HU 71833 A2	28-02-1996
		JP 7149762 A	13-06-1995
		NO 943616 A	31-03-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11952

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5532241	A		PL 305216 A1	03-04-1995
			RU 2132848 C1	10-07-1999
			SK 118494 A3	10-05-1995
			ZA 9407622 A	16-05-1995
WO 0005225	A	03-02-2000	AU 5033899 A	14-02-2000
			BR 9912299 A	20-11-2001
			CN 1309654 T	22-08-2001
			WO 0005225 A1	03-02-2000
			EP 1098892 A1	16-05-2001
			HU 0102622 A2	28-12-2001
			NO 20010333 A	19-01-2001